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Endovascular therapy (EVT) has increasingly become the initial clinical option for treatment of lower extremity
peripheral arterial disease (PAD), not only for patients with claudication, but also for those with critical limb ischemia.
Despite this major clinical practice paradigm shift, the outcomes of EVT for PAD are difficult to evaluate and compare
with established surgical benchmarks because of the lack of prospective, randomized trials, incomplete characterization of
indications for intervention, mixing of arterial segments and extent of disease treated, the multiplicity of EVT techniques
used, the exclusion of early treatment failures, crossover to open bypass during follow-up, and the frequent lack of
intermediate and long-term patency and limb salvage rates in life-table format. These data limitations are especially
problematic when one tries to assess the outcome of EVT in patients with diabetes. The purpose of the present report is
to succinctly review and objectively analyze available data regarding the results of EVT in patients with diabetes. ( J Vasc
Surg 2010;52:92S-95S.)Diabetes and cigarette smoking are the most important
risk factors for developing peripheral arterial disease
(PAD).1 The coronary literature2-4 clearly demonstrates a
significantly increased mortality rate and need for repeat
interventions in patients with diabetes who undergo angio-
plasty compared to surgical bypass. The increased mortality
rate and increased rate of secondary interventions imply
that patients with diabetes have higher restenosis rates after
endovascular interventions. In contrast, there are no pro-
spective randomized studies comparing infrainguinal endo-
vascular therapy (EVT) with surgical bypass in patients with
diabetes. Patients with diabetes more commonly present
with involvement of the deep femoral and tibial arteries
compared with patients who are not diabetic; however,
patients with diabetes present with heterogeneous patterns
and may have arterial occlusive disease in any vascular
territory. EVT is less effective in smaller arteries such as
tibial arteries, compared to the femoropopliteal arteries5,6
regardless of the presence of diabetes.
Factors that influence the outcome of EVT. Be-
cause PAD has multiple risk factors and the severity of
disease encompasses a vast range, large cohorts of patients
with PAD will include a myriad of presentations. This
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92Scomplicates the analysis of outcomes for claudication and
critical limb ischemia (CLI) treatment, especially in patients
with diabetes. Even the definition of CLI is not optimal.
Consider that in the placebo arm of the Circulase trial,7
patients with CLI who did not undergo revascularization
had a limb salvage rate of 87% at 6 months. This was similar
to the amputation-free survival rates seen in both the open
surgery and EVT arms of the BASIL trial.8 The heteroge-
neity of the patients combined with the lack of a more
specific working definition for CLI makes defining out-
comes challenging. Factors that have been shown to nega-
tively impact EVT outcomes include: the indication9,10 for
the procedure, lesion length,5 Trans Atlantic Inter-Societal
Consensus (TASC) classification,11 runoff score,12-15 oc-
clusion vs stenosis,5 renal failure,13 and excessive or heavy
calcification16,17 (Table). Evaluating the impact of diabetes
on EVT remains difficult because patients with diabetes
more commonly have multiple adverse risk factors.
The influence of diabetes on outcomes of EVT and
open surgical bypass. Technical success rates for infrain-
guinal endovascular interventions are worse in the tibial
arteries18-21 compared to the femoropopliteal arteries.13,22
Similarly, heavy lesion calcification portends technical fail-
ure.16,17 Because patients with diabetes are more suscepti-
ble to developing more heavily calcified atherosclerotic
arteries and tibial artery occlusive disease, it is intuitive that
patients with diabetes would have lower technical success
rates compared with patients without diabetes. In a retro-
spective review of infrainguinal endovascular interventions
primarily in the femoropopliteal segment, Lazaris et al23
found a decreased technical success rate in patients with
diabetes, 81% compared to 93% (P  .05) in patients
without diabetes. More dramatically, they found a signifi-
cantly increased rate of complications in patients with dia-
betes, 16.7% vs 3.9% (P  .03).
The available infrainguinal revascularization data are
primarily nonrandomized and retrospective. Nonetheless,
opopli
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onstrate no difference in the technical success or patency
rates of patients with diabetes compared to patients without
diabetes.24,25 In contrast, DeRubertis et al26 evaluated
1000 consecutive percutaneous interventions in the femo-
ropopliteal and tibial arteries and found a diminished pri-
mary patency rate in patients with diabetes (hazard ratio
[HR], 1.7). In fact, diabetes was one of the most important
risk factors affecting primary patency, second only to the
indication for the procedure (HR, 2.5). In a prospective,
nonrandomized study, Dick et al27 compared both surgical
and endovascular interventions for iliac, femoropopliteal,
and tibial artery occlusive disease and found poorer sus-
tained clinical benefit in patients with diabetes. Sustained
clinical benefit was defined as improvement in Rutherford
et al’s28 category, amputation-free survival, and freedom
from target extremity revascularization; however, the dif-
ference was primarily due to target extremity revasculariza-
Table. Factors affecting primary patency after endovascula
Series
Number
treated
Average lesion
length
Multilevel interventions
DeRubertis 200726 (79% fem-
pop, 21% tibial)
(86% primary, 14%
reinterventions)
1000 NR
Femoropopliteal interventions
Cheng 200310 (stent only) 73 16 cm
Johnston 199212 (PTA only) 254 10 cm
Clark 200113 (PTA only) 219 4 cm
Jamsen 200314 (PTA only) 218 5.2 cm
Ihnat 200815 (stent only) 109 15.7 cm
Lugmayr 200230 (stent only) 54 3-4 cm
Sabeti 200531 (stent only) 65 16 cm (all greater tha
Dearing 200932 (primary
stenting)
161 12.9 cm
Tibial interventions
Vraux 200018 40 NR
Vraux 200619 50 NR
Giles 200821 176 NR
CAD, Coronary artery disease; CLI, critical limb ischemia; fem-pop, femor
TASC, TransAtlantic InterSocietal Classification.tion. Both secondary sustained clinical benefit and limbsalvage were equivalent to patients without diabetes. The
authors concluded that multiple revascularizations might
be required in patients with diabetes to achieve similar limb
salvage rates.
EVT for PAD of the femoropopliteal arteries. These
reports are comprised of heterogeneous groups of patients
with both multilevel and single-level arterial occlusive dis-
ease involving different arterial territories. However, some
clinical investigators have focused on the results of EVT in
a single arterial territory. In a registry of 219 limbs that
underwent femoropopliteal angioplasty, Clark et al13
found diabetes to be significantly associated with reduced
primary patency (relative risk [RR], 5.5; this was a stronger
association than renal failure (RR, 4.0), but weaker than
poor tibial runoff (RR, 8.5). Another retrospective study29
compared subintimal angioplasty with placement of cov-
ered stents in long-segment superficial femoral artery oc-
clusions, and found diabetes to be strongly associated with
rapy: comparative results of published series
Primary
patency
Technical failures
included
Factors affecting
patency (RR)
60% 1 y
50% 2 y
48% 2.5 y
0% CLI (2.5)
Diabetes (1.7)
Hypercholesterolemia (1.7)
CAD (1.4)
TASC D (1.3)
56% 1 y
35% 2 y
22% 4 y
22% 4 y
0% Indication
Lesion 10 cm
70% 1 y
57% 2 y
50% 3 y
43% 5 y
4% Runoff
87% 1 y
80% 2 y
69% 3 y
55% 5 y
5% Runoff (8.5)
Diabetes (5.5)
Renal failure (4.0)
46% 1 y
25% 5 y
16.5% Runoff
63% 1 y
52% 2 y
52% 3 y
0% Runoff (2.6)
TASC D (5.5)
87% 1 y
85% 2 y
76% 3 y
0% Diabetes
) 54% 1 y 0% Diabetes (3.8)
70% 1 y
55% 2 y
39% 3 y
4.4% TASC D (6.2)
TASC C (3.8)
Hypercholesterolemia (2.1)
56% 1 y 22% 10-cm occlusion
46% 1 y 18% 10-cm occlusion
Extension into popliteal artery
53% 1 y
51% 2 y
7% TASC D (2.8)
No target (2.2)
teal; NR, not reported; PTA, percutaneous angioplasty; RR, relative risk;r the
n 5 cmdecreased primary patency (HR, 7.2). Investigators30,31
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ing and found diabetes significantly decreased patency
rates, whereas others15,32 have not. Baril et al33 evaluated
predominantly claudicants with TASC II B and C femoro-
popliteal lesions, and did not find an association between
diabetes and restenosis. Bakken et al34 separately evaluated
patients with claudication and critical limb ischemia who
underwent EVT of superficial femoral artery occlusive dis-
ease. In the claudication group, insulin-dependent diabet-
ics maintained primary patency rates similar to patients
without diabetes, but decreased assisted patency rates and
increased restenosis rates at 3 years. Conversely, in patients
with CLI, diabetes did not affect patency or restenosis rates,
although it did negatively impact limb salvage rates.
EVT for PAD of the tibial arteries. In the tibial
arteries, Giles et al21 evaluated 176 patients, 72% of whom
had diabetes and underwent infrapopliteal artery angio-
plasty, and found only TASC D lesions and poor runoff
predicted restenosis, reintervention, decreased patency,
and reduced limb salvage rates. Sadek et al35 treated 89
limbs with tibial artery EVT, and found improved second-
ary patency in patients who underwent endovascular inter-
ventions for multilevel disease compared to isolated tibial
artery disease. Interestingly, the limb salvage rates were
equivalent. Similarly, Gray et al36 reviewed their database of
patients treated for tibial artery occlusive disease. They
found that one-third of patients had isolated tibial artery
disease; the remainder had multilevel occlusive disease.
Patients with isolated tibial artery disease had worse out-
comes with respect to overall survival, amputation-free
survival, limb salvage, maintenance of ambulatory status,
independent living, and secondary patency. Interestingly, iso-
lated tibial disease was not an independent predictor for the
worse outcomes, but instead, the presence of tissue loss and
end-stage renal disease (ESRD) correlatedmost strongly with
poor outcomes. These authors suggested that isolated tibial
artery disease is a surrogate marker for more severe tissue loss.
None of these studies found an association between diabetes
and reduced EVT patency rates.
Limb salvage, morbidity, and mortality. The surgi-
cal bypass literature24,37 generally suggests that limb sal-
vage rates are not significantly worse in patients with dia-
betes compared to those without. Conversely, Bakken et
al34 found decreased limb salvage rates in patients with
insulin-dependent diabetes mellitus treated with EVT for
femoropopliteal artery occlusive disease, despite similar pa-
tency rates. This finding remained statistically significant
after patients with ESRD were excluded. Similarly, Conrad
et al38 evaluated EVT of the femoropopliteal arteries in 110
patients with critical limb ischemia (15% with ESRD) and
found diabetes significantly increased the risk of amputa-
tion (HR, 11.5). Conversely, Dick et al27 found no differ-
ence in limb salvage rates of patients with diabetes, and
attributed their results to close surveillance and an aggres-
sive policy of multiple, secondary interventions.
Because endovascular therapy is minimally invasive,
unless a major bleeding complication occurs, mortality is
usually more a reflection of the patient’s underlying comor-bidities rather than the stress of the procedure itself. Jamsen
et al14 also found an increased mortality rate for patients
with diabetes (odds ratio, 2.0) in 304 patients who under-
went infrainguinal revascularization with an endovascular
attempt first approach; only 10.5% underwent surgical by-
pass. The BASIL trial8 did not detect a significant decrease
in survival rates for patients with diabetes, although less
than one-third of patients in this trial of EVT vs bypass for
severe limb ischemia had diabetes. Instead, the investiga-
tors found a decrease in survival for patients living more
than 2 years who underwent EVT first.
In summary, patients with diabetes mellitus undergo-
ing infrainguinal EVT are a heterogeneous group, and
further investigation is required to more completely under-
stand the impact of diabetes on outcomes. Patients under-
going EVT with diabetes most likely have higher rates of
technical failure and subsequent amputation. Also, patients
with diabetes probably have higher rates of restenosis after
EVT in the femoropopliteal arteries; data are less clear for
tibial EVT. The impact of diabetes on patency and resteno-
sis rates in the femoropopliteal arteries is probably less
important than TASC classification and tibial artery runoff.
Among patients with diabetes and CLI, those presenting
with isolated tibial artery occlusive disease are more likely to
have more advanced tissue loss, ESRD, and a worse prog-
nosis.
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